• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Preparation, drug release, and cell growth inhibition of a gelatin: doxorubicin conjugate.明胶-阿霉素缀合物的制备、药物释放和细胞生长抑制。
Pharm Res. 2013 Aug;30(8):2087-96. doi: 10.1007/s11095-013-1065-9. Epub 2013 May 18.
2
Comparative studies of polyethylenimine-doxorubicin conjugates with pH-sensitive and pH-insensitive linkers.聚亚乙基亚胺-阿霉素缀合物的 pH 敏感和 pH 不敏感连接物的比较研究。
J Biomed Mater Res A. 2013 May;101(5):1336-44. doi: 10.1002/jbm.a.34450. Epub 2012 Oct 15.
3
Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification.具有pH控制活化功能的HPMA共聚物-阿霉素缀合物的性质:聚合物链修饰的影响
J Control Release. 2006 Sep 28;115(1):26-36. doi: 10.1016/j.jconrel.2006.06.028. Epub 2006 Jun 30.
4
Intracellularly Actuated Quantum Dot-Peptide-Doxorubicin Nanobioconjugates for Controlled Drug Delivery via the Endocytic Pathway.基于内吞途径的细胞内响应型量子点-肽-阿霉素纳米生物偶联物用于药物控释。
Bioconjug Chem. 2018 Jan 17;29(1):136-148. doi: 10.1021/acs.bioconjchem.7b00658. Epub 2017 Dec 21.
5
Polymeric micelles encapsulating pH-responsive doxorubicin prodrug and glutathione-activated zinc(II) phthalocyanine for combined chemotherapy and photodynamic therapy.载 pH 响应型阿霉素前药和谷胱甘肽激活型锌(II)酞菁的聚合物胶束用于联合化疗和光动力治疗。
J Control Release. 2018 Jul 28;282:46-61. doi: 10.1016/j.jconrel.2018.04.030. Epub 2018 Apr 16.
6
EGCG/gelatin-doxorubicin gold nanoparticles enhance therapeutic efficacy of doxorubicin for prostate cancer treatment.EGCG/明胶-阿霉素金纳米粒增强阿霉素治疗前列腺癌的疗效。
Nanomedicine (Lond). 2016 Jan;11(1):9-30. doi: 10.2217/nnm.15.183. Epub 2015 Dec 11.
7
HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity.具有pH值控制阿霉素释放功能的HPMA共聚物:体外细胞毒性和体内抗肿瘤活性
J Control Release. 2003 Feb 21;87(1-3):33-47. doi: 10.1016/s0168-3659(02)00348-6.
8
Novel folated and non-folated pullulan bioconjugates for anticancer drug delivery.新型叶酸和非叶酸化支链淀粉生物缀合物用于抗癌药物递送。
Eur J Pharm Sci. 2011 Apr 18;42(5):547-58. doi: 10.1016/j.ejps.2011.02.012. Epub 2011 Mar 1.
9
Drug Release Behavior of Doxorubicin Hydrochloride-Loaded Poly(-Lactic Acid)/Hydroxyapatite/Gelatin by Surface Modification of Hydroxyapatite.通过羟基磷灰石表面改性研究载盐酸多柔比星的聚(-乳酸)/羟基磷灰石/明胶的药物释放行为
J Nanosci Nanotechnol. 2018 Oct 1;18(10):7225-7230. doi: 10.1166/jnn.2018.15507.
10
Coordinated pH/redox dual-sensitive and hepatoma-targeted multifunctional polymeric micelle system for stimuli-triggered doxorubicin release: Synthesis, characterization and in vitro evaluation.用于刺激触发阿霉素释放的协同pH/氧化还原双敏感及肝癌靶向多功能聚合物胶束系统:合成、表征及体外评价
Int J Pharm. 2016 Mar 30;501(1-2):221-35. doi: 10.1016/j.ijpharm.2016.02.002. Epub 2016 Feb 3.

引用本文的文献

1
Insights on Chemical Crosslinking Strategies for Proteins.蛋白质化学交联策略的研究进展
Molecules. 2022 Nov 22;27(23):8124. doi: 10.3390/molecules27238124.
2
Biopolymer Hydrogel Scaffolds Containing Doxorubicin as A Localized Drug Delivery System for Inhibiting Lung Cancer Cell Proliferation.含有阿霉素的生物聚合物水凝胶支架作为抑制肺癌细胞增殖的局部给药系统
Polymers (Basel). 2021 Oct 17;13(20):3580. doi: 10.3390/polym13203580.
3
Biocompatible and biodegradable fibrinogen microspheres for tumor-targeted doxorubicin delivery.用于肿瘤靶向阿霉素递送的生物相容性和可生物降解的纤维蛋白原微球。
Int J Nanomedicine. 2015 Sep 1;10 Spec Iss(Spec Iss):101-11. doi: 10.2147/IJN.S88381. eCollection 2015.
4
Carbodiimide induced cross-linking, ligand addition, and degradation in gelatin.碳二亚胺诱导明胶发生交联、配体添加及降解。
Mol Pharm. 2015 Mar 2;12(3):783-93. doi: 10.1021/mp5006118. Epub 2015 Feb 6.

本文引用的文献

1
Adsorption and degradation of doxorubicin from aqueous solution in polypropylene containers.水中多柔比星在聚丙烯容器中的吸附和降解。
AAPS PharmSciTech. 2013 Mar;14(1):74-7. doi: 10.1208/s12249-012-9885-1. Epub 2012 Dec 11.
2
HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity.HPMA 共聚物-阿霉素偶联物:分子量和结构对体内分布和体内活性的影响。
J Control Release. 2012 Dec 28;164(3):346-54. doi: 10.1016/j.jconrel.2012.06.029. Epub 2012 Jun 30.
3
In vivo evaluation of doxorubicin-loaded (PEG)(3)-PLA nanopolymersomes (PolyDoxSome) using DMBA-induced mammary carcinoma rat model and comparison with marketed LipoDox™.采用 DMBA 诱导的乳腺癌大鼠模型对载多柔比星的(PEG)(3)-PLA 纳米聚合物囊泡(PolyDoxSome)进行体内评价,并与市售的 LipoDox™进行比较。
Pharm Res. 2012 Sep;29(9):2522-33. doi: 10.1007/s11095-012-0783-8. Epub 2012 Jun 6.
4
Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy.可生物降解星形 HPMA 聚合物-药物偶联物:生物降解性、分布和抗肿瘤功效。
J Control Release. 2011 Sep 25;154(3):241-8. doi: 10.1016/j.jconrel.2011.06.015. Epub 2011 Jun 15.
5
Bioresorbable Vesicles Formed through Spontaneous Self-Assembly of Amphiphilic Poly(ethylene oxide)-block-polycaprolactone.通过两亲性聚(环氧乙烷)-嵌段-聚己内酯的自发自组装形成的生物可吸收囊泡。
Macromolecules. 2006 Mar 7;39(5):1673-1675. doi: 10.1021/ma0519009.
6
The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly(gamma-benzyl L-glutamate)-b-hyaluronan polymersomes.载多柔比星聚(γ-苄基 L-谷氨酸)-b-透明质酸聚合物囊泡的细胞内药物递送和抗肿瘤活性。
Biomaterials. 2010 Apr;31(10):2882-92. doi: 10.1016/j.biomaterials.2009.12.043. Epub 2010 Jan 6.
7
Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities.HPMA 共聚物缀合物是否有作为临床有用的纳米药物的未来?对当前现状和未来机遇的批判性综述。
Adv Drug Deliv Rev. 2010 Feb 17;62(2):272-82. doi: 10.1016/j.addr.2009.12.005. Epub 2009 Dec 11.
8
Preclinical evaluation of linear HPMA-doxorubicin conjugates with pH-sensitive drug release: efficacy, safety, and immunomodulating activity in murine model.线性 HPMA-阿霉素缀合物的临床前评价:具有 pH 敏感性药物释放的疗效、安全性和在小鼠模型中的免疫调节活性。
Pharm Res. 2010 Jan;27(1):200-8. doi: 10.1007/s11095-009-9999-7. Epub 2009 Nov 6.
9
In vitro evaluation of surface functionalized gelatin nanoparticles for macrophage targeting in the therapy of visceral leishmaniasis.体外评价表面功能化明胶纳米颗粒对内脏利什曼病治疗中巨噬细胞靶向的作用。
J Drug Target. 2010 Feb;18(2):93-105. doi: 10.3109/10611860903115290.
10
Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts.PGG-紫杉醇,一种紫杉醇的新型高分子制剂,在荷瘤 NCI-460 肺癌裸鼠中的药代动力学和组织分布。
Cancer Chemother Pharmacol. 2010 Feb;65(3):515-26. doi: 10.1007/s00280-009-1058-x. Epub 2009 Jul 11.

明胶-阿霉素缀合物的制备、药物释放和细胞生长抑制。

Preparation, drug release, and cell growth inhibition of a gelatin: doxorubicin conjugate.

机构信息

Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, 600 South 43rd Street, Philadelphia, Pennsylvania 19104, USA.

出版信息

Pharm Res. 2013 Aug;30(8):2087-96. doi: 10.1007/s11095-013-1065-9. Epub 2013 May 18.

DOI:10.1007/s11095-013-1065-9
PMID:23686374
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3700642/
Abstract

PURPOSE

To demonstrate the feasibility of a novel macromolecular delivery system for doxorubicin (DOX) which combines pH dependent DOX release with a high molecular weight and biodegradable gelatin carrier.

METHODS

DOX was conjugated to gelatin using an acid labile hydrazone bond and a glycylglycine linker. The gelatin-doxorubicin conjugate (G-DOX) was evaluated for hydrazide and DOX content by spectrophotometry, molecular weight by HPLC-SEC, in vitro DOX release at various pH, and cell growth inhibition using EL4 mouse lymphoma and PC3 human prostate cells.

RESULTS

G-DOX hydrazide and DOX content was 47% and 5-7%, respectively of theoretical gelatin carboxylic acid sites. During preparation of G-DOX, the molecular weight decreased to 22 kDa. DOX release was 48% in pH 4.8 phosphate buffer, 22% at pH 6.5, but 10% at pH 7.4. The G-DOX IC50 values in EL4 and PC3 cells were 0.26 μM and 0.77 μM, respectively; the latter value 3 times greater than that of free DOX.

CONCLUSIONS

A 22 kDa macromolecular DOX conjugate containing 3.4-5.0% w/w DOX has been prepared. The pH dependent drug release in combination with a biodegradable gelatin carrier offer potential therapeutic advantages of enhanced tumor cell localization and reduced systemic toxicities of the drug.

摘要

目的

展示一种新型的阿霉素(DOX)大分子递药系统的可行性,该系统将 DOX 的 pH 依赖性释放与高分子量和可生物降解的明胶载体相结合。

方法

通过酸不稳定的腙键和甘氨酰甘氨酸接头将 DOX 与明胶偶联。通过分光光度法评估明胶-阿霉素缀合物(G-DOX)的酰肼和 DOX 含量、高效液相色谱-SEC 的分子量、不同 pH 下的体外 DOX 释放以及使用 EL4 小鼠淋巴瘤和 PC3 人前列腺细胞的细胞生长抑制。

结果

G-DOX 酰肼和 DOX 含量分别为理论明胶羧酸部位的 47%和 5-7%。在制备 G-DOX 期间,分子量降至 22 kDa。在 pH 4.8 的磷酸盐缓冲液中 DOX 释放 48%,在 pH 6.5 时释放 22%,但在 pH 7.4 时释放 10%。G-DOX 在 EL4 和 PC3 细胞中的 IC50 值分别为 0.26 μM 和 0.77 μM,后者是游离 DOX 的 3 倍。

结论

已经制备了一种包含 3.4-5.0%w/w DOX 的 22 kDa 大分子 DOX 缀合物。这种 pH 依赖性药物释放与可生物降解的明胶载体相结合,为增强肿瘤细胞定位和降低药物的全身毒性提供了潜在的治疗优势。